Simple Summary Immune escape mechanisms have been identified in every step of lung
tumorigenesis. A heterogeneous ensemble of immune evasion processes shapes the …

Immune checkpoint inhibitors have transformed the prognosis and treatment paradigm of
many cancer types, through the potential for durable responses. However, the majority of …

Pancreatic adenocarcinoma (PAAD) is the eighth leading cause of cancer-related mortality
that causes serious physical and mental burden to human. Reactive oxygen species …

Background Despite the great achievements made in immune-checkpoint-blockade (ICB) in
cancer therapy, there are no effective predictive biomarkers in gastrointestinal (GI) cancer …

Several clinical trials have shown the safety and effectiveness of PD-1/PD-L1 inhibitors in
neoadjuvant therapy in resectable non-small cell lung cancer (NSCLC). However, 18–83 …

Chromosomal abnormalities, consisting of numerical and structural chromosome
abnormalities, are a common characteristic of cancer. Numerical chromosome …

The clinical outcome of resectable non–small‐cell lung cancer (NSCLC) patients receiving
neoadjuvant chemoimmunotherapy is good but varies greatly. In addition, the pathological …

Background The early-stage lung adenocarcinoma (LUAD) rate has increased with
heightened public awareness and lung cancer screening implementation. Lipid metabolism …

Cancer immunotherapy, which aims to control the immune system to eradicate cancer cells
and prevent their spread, needs to be personalized because anticancer immune responses …

Introduction Although gene-level copy number alterations have been studied as a potential
biomarker of immunotherapy efficacy in NSCLC, the impact of aneuploidy burden and …